Oncology Central

What is the future potential of the PI3K pathway in colorectal cancer treatment?

0

Therapeutic options for treating patients with metastatic colorectal cancer (CRC) have increased markedly over the past decade. Recent improvements in overall survival rates from 10 to 24 months have been achieved through the introduction of molecularly targeted agents to complement traditional cytotoxics, including agents directed against the EGF receptor (EGFR) pathway (cetuximab and panitumumab) and angiogenesis (bevacizumab, aflibercept and regorafenib).

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.

Share:

Insights

Videos

News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.